The use of polatuzumab vedotin in place of vincristine in R-mini-CHOP may lead to an increase in gastrointestinal adverse events in frail patients with diffuse large B-cell lymphoma.
Nicholas Wrigley
Articles by Nicholas Wrigley
With BMS-986158 plus ruxolitinib or fedratinib treatment in patients with myelofibrosis, reduction in splenic volume was reported among all patients in part 1A and became more robust at week 24.
The primary end point was not reached in the phase 3 SOLSTICE study.
A subgroup analysis of ENGOT-EN6-NSGO/GOG-3031/RUBY has displayed positivity efficacy in patients with advanced/recurrent endometrial cancer.
Cabozantinib and Immunotherapy Combination Improves Efficacy in Advanced Renal Cell Cancer Subgroups
Cabozantinib improved outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among poor-risk patients in combination with nivolumab and ipilimumab.
Findings from the second interim analysis of the phase 3 MAGNITUDE study showed the positive benefit of niraparib plus abiraterone and prednisone in metastatic castration-resistant prostate cancer.
According to initial data presented at the 2023 Gastrointestinal Cancers Symposium, the novel, personalized, tumor-informed brPROPHET technology was more sensitive in detecting molecular residual disease vs other assays.
